ReviewAlzheimer's research & therapy2014
Neuroimaging characteristics of dementia with Lewy bodies.
Review in Alzheimer's research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sex differences inFrontiers in dementia · 2025Pooled it
- Machine learning classification and regional differentiation of neuropathologically-confirmed Alzheimer's disease and comorbid Lewy body disease.Communications medicine · 2026Article
- Automated Imaging Differentiation for Dementia: Including Alzheimer Disease Dementia and Dementia with Lewy Bodies.Neurology open access · 2026Article
- Seven tesla MRI reveals amygdala and hippocampal subfield atrophy in dementia with Lewy bodies.Alzheimer's research & therapy · 2026Article
- Alpha-synuclein overexpression reduces neural activity within a basal ganglia vocal nucleus in a zebra finch model.PloS one · 2026Article
- Review
- Separating dementia with Lewy bodies from Alzheimer's disease dementia using a volumetric MRI classifier.European radiology · 2025Article
- Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer's disease copathologies.NPJ Parkinson's disease · 2025Article
- Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.Journal of medicinal chemistry · 2025Review
- AI-Y: An AI Checklist for Population Ethics Across the Global Context.Current epidemiology reports · 2025Review
- Longitudinal Free-Water Changes in Dementia with Lewy Bodies.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Alteration of medial temporal lobe metabolism related to Alzheimer's disease and dementia with lewy bodies.Alzheimer's research & therapy · 2024Article
- Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies.NPJ Parkinson's disease · 2024Article
- PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.American journal of nuclear medicine and molecular imaging · 2024Review
- Automated brain segmentation and volumetry in dementia diagnostics: a narrative review with emphasis on FreeSurfer.Frontiers in aging neuroscience · 2024Review
- Memories and mimics: unveiling the potential of FDG-PET in guiding therapeutic approaches for neurodegenerative cognitive disorders.Frontiers in neurology · 2024Review
- Differences in Cognitive Trajectories of Dementia: Comparison of Alzheimer's Disease Dementia and Dementia with Lewy Bodies in a Korean Patient Cohort.Dementia and geriatric cognitive disorders · 2024Article
- Differential diagnosis of neurodegenerative dementias with the explainable MRI based machine learning algorithm MUQUBIA.Scientific reports · 2023Article
- The use of neuroimaging techniques in the early and differential diagnosis of dementia.Molecular psychiatry · 2023Review
- Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review summarises the findings and applications from neuroimaging studies in dementia with Lewy bodies (DLB), highlighting key differences between DLB and other subtypes of dementia. We also discuss the increasingly important role of imaging biomarkers in differential diagnosis and outline promising areas for future research in DLB. DLB shares common clinical, neuropsychological and pathological features with Parkinson's disease dementia and other dementia subtypes, such as Alzheimer's disease. Despite the development of consensus diagnostic criteria, the sensitivity for differential diagnosis of DLB in clinical practice remains low and many DLB patients will be misdiagnosed. The importance of developing accurate imaging markers in dementia is highlighted by the potential for treatments targeting specific molecular abnormalities as well as the responsiveness to cholinesterase inhibitors and marked neuroleptic sensitivity of DLB. We review various brain imaging techniques that have been applied to investigate DLB, including the characteristic nigrostriatal degeneration in DLB using positron emission tomography (PET) and single-photon emission computed tomography (SPECT) tracers. Dopamine transporter loss has proven to reliably differentiate DLB from other dementias and has been incorporated into the revised clinical diagnostic criteria for DLB. To date, this remains the 'gold standard' for diagnostic imaging of DLB. Regional cerebral blood flow, 18 F-fluorodeoxygluclose-PET and SPECT have also identified marked deficits in the occipital regions with relative sparing of the medial temporal lobe when compared to Alzheimer's disease. In addition, structural, diffusion, and functional magnetic resonance imaging techniques have shown alterations in structure, white matter integrity, and functional activity in DLB. We argue that the multimodal identification of DLB-specific biomarkers has the potential to improve ante-mortem diagnosis and contribute to our understanding of the pathological background of DLB and its progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.